Company · Private
Deciduous Therapeutics
Develops small molecules that recruit the innate immune system to clear senescent cells rather than killing them directly.
EvidenceEarly
Listing
Private
Ticker
—
Headquarters
San Francisco, US
Founded
2019
Technology
Immune-mediated senescent cell clearance
Category
Market cap
Private
Longevity thesis
Immune clearance may produce durable benefit with lower off-target toxicity than direct-kill senolytics.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| DT-201 | Preclinical | Metabolic disease |
Recent developments
- 11 Jun 2026Presented preclinical metabolic reversal data.
Scientific evidence
EvidenceEarly
Animal data only.
LONGEFI analysis
A differentiated mechanism inside a field that has struggled with tolerability. Worth tracking as a scientific hedge against direct-kill senolytics failing.
Analysis is research commentary. It is not investment advice or a recommendation.